Gilead Sciences Overview
Gilead Sciences (GILD) has a ROE of -27.59%, below the Healthcare sector average of 20.86%.
Get informed when a big investor buys or sells
+ Follow-27.59%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
The latest ROE for GILD is -27.59%. That is below the Healthcare sector average of 20.86%. Investors often review this figure alongside Gilead Sciences's historical trend and sector peers before judging valuation or financial health.
Against Healthcare companies, GILD currently prints -27.59% for ROE, while the sector average sits near 20.86%. That is roughly 232.3% below the sector mean. Large gaps often invite a closer look at Gilead Sciences's growth, margins, and balance sheet.
Return on Equity shows how effectively Gilead Sciences converts resources into returns. At -27.59%, GILD may look efficient or underperforming depending on peer benchmarks and trend direction. Pair the percentage with revenue growth and leverage for a fuller health check.
After noting GILD's ROE (-27.59%), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.
This page's peer comparison chart is the fastest way to stack Gilead Sciences's ROE against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.
